---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-009387"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T02:34:12.107444+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio enters first patients into pivotal Phase 3 Alzheimer's study of buntanetap

## Summary
- First two patients enrolled in pivotal Phase 3 trial of buntanetap for early Alzheimer's disease.
- Trial is 18-month, randomized, placebo-controlled, double-blind with primary endpoints ADAS-Cog13 and ADCS-iADL.
- Over 750 participants expected across ~100 US sites; FDA-approved protocol.
- Company raised $21M gross from public offering of 5.25M units to fund initial 6 months; 12-month from warrant exercises.
- CEO cites prior Phase 2/3 data showing cognitive improvement and no safety concerns.

## SEC filing metadata
- accession: 0001104659-25-009387
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465925009387/0001104659-25-009387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465925009387/tm255497d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-009387
- JSON: https://secwatch.observer/filing/0001104659-25-009387.json
- Plain text: https://secwatch.observer/filing/0001104659-25-009387.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.